Eli Lilly and Company (India) has acknowledged the action taken by the Haryana Drug Control Authority in seizing counterfeit products falsely labelled as Mounjaro in Gurugram, Haryana.

The company clarified that the seized products were not manufactured by Lilly and did not originate from its authorised and verified supply chain. Following the authority’s investigation, most of the counterfeit stock has been recovered. As per regulatory directions, the supply of genuine Lilly medicines through authorised distributors and licensed pharmacies remains unaffected.

“We recognise the efforts of the Haryana regulatory authority in addressing counterfeit medicines and supporting measures aimed at protecting patient safety,” said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). “Lilly takes any act of counterfeiting very seriously. Counterfeit products are not manufactured under approved quality controls and may pose significant risks to patient safety and public health."

Tucker added further: "We will continue to take steps to protect patients from the risks of counterfeit and other unsafe products worldwide, including working with regulators and law enforcement. We urge patients to procure Lilly products only through authorised distributors or licensed pharmacies, and on a valid prescription. Further, we want to clarify that Lilly’s patented tirzepatide molecule is marketed in India under two brand names — Mounjaro® and Yurpeak®.”

The company also cautioned that counterfeit medicines may closely resemble genuine products, making vigilance essential for patients, caregivers, and healthcare professionals.

Warning signs may include products sourced from unauthorised or unlicensed channels, tampered or damaged packaging, missing batch numbers, expiry dates or manufacturer details, as well as inconsistencies such as spelling errors, unfamiliar logos, or incorrect labelling.